Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.64 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.64 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | AMY2A | P04746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466465 | 0.98 | LGALS3 (0.67) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL29533372 | 0.98 | LGALS3 (0.67) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL29399259 | 0.97 | LGALS3 (0.63) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL117333 | 0.95 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL4125477 | 0.95 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL10524839 | 0.95 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL14268473 | 0.95 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL20555908 | 0.95 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL9398176 | 0.95 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL4309100 | 0.95 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195172-B2 | Reduction of gastrointestinal tract colonisation by Campylobacter | Akeso Biomedical, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170231945-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | Akeso Biomedical, Inc. | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195172-B2 | Reduction of gastrointestinal tract colonisation by Campylobacter | FABP2, MLN, SLC10A2 | LGALS3 522/4885LGALS8 971/4885LGALS4 502/4885 |
| US-20170231945-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | FABP2, MLN, MLNR | LGALS3 673/4885LGALS8 1133/4885LGALS4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.